Dermatomyositis

14 trials 10 recruiting MedDRA PT
14 Registered trials
10 Recruiting
11 Unique sponsors
11 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
JAK inhibitor 3 substances
Monoclonal antibody 1 substance
EGFR inhibitor 1 substance
Phase III: 4 Phase II/III: 1 Phase II: 7 Phase I (Other): 2

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase III

4 trials
  • AstraZeneca AB Commercial
    ANIFROLUMAB
    2023-504022-19-01 13 countries 2024 n=84 Orphan
    Recruiting
  • Pfizer Inc. Commercial
    DAZUKIBART; HUMANISED IGG1K MONOCLONAL ANTIBODY AGAINST INTERFERON BETA
    2022-502739-20-00 10 countries 2023 n=79 Orphan
    Recruiting
  • Pfizer Inc. Commercial
    DAZUKIBART
    2024-514648-10-00 6 countries 2025 n=23 Orphan
    Recruiting
  • Priovant Therapeutics Inc. Commercial
    BREPOCITINIB TOSILATE
    2022-500367-12-00 12 countries 2022 n=126
    Recruiting

Phase II/III

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    BARICITINIB
    2024-511899-32-00 1 country 2022 n=62
    Recruiting

Phase II

7 trials
  • Argenx Commercial
    EMPASIPRUBART
    2023-508337-14-00 4 countries 2025 n=19
    Ended
  • Galapagos Commercial
    GLPG3667 FUMARATE
    2022-501097-19-00 10 countries 2023 n=32
    Ended
  • Merck Healthcare KGaA Commercial
    ENPATORAN
    2022-501351-82-00 6 countries 2023 n=15
    Ended
  • Medical University Of Vienna Academic
    UPADACITINIB
    2024-513681-19-00 1 country 2025 n=10
    Recruiting
  • Universitaetsklinikum Schleswig-Holstein AöR Academic
    ALDESLEUKIN
    2023-510297-14-00 1 country 2024 n=112 Orphan
    Recruiting
  • University Medical Center Utrecht Academic
    FILGOTINIB
    2022-502968-20-01 1 country n=60
    Not authorised
  • University Medical Center Utrecht Academic
    FILGOTINIB
    2022-502968-20-02 1 country 2024 n=40
    Recruiting

Phase I (Other)

2 trials
  • Chugai Pharmaceutical Co. Ltd. Commercial
    IMP not specified
    2023-507692-21-00 14 countries 2024 n=87
    Recruiting
  • Chugai Pharmaceutical Co. Ltd. Commercial
    IMP not specified
    2024-511346-39-00 14 countries 2025 n=78
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Chugai Pharmaceutical Co. Ltd. Commercial 2 Phase I (Other) 2
Pfizer Inc. Commercial 2 Phase III 2
University Medical Center Utrecht Academic 2 Phase II 1
Argenx Commercial 1 Phase II 0
Galapagos Commercial 1 Phase II 0
Merck Healthcare KGaA Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase III 1
Priovant Therapeutics Inc. Commercial 1 Phase III 1
Assistance Publique Hopitaux De Paris Academic 1 Phase II/III 1
Medical University Of Vienna Academic 1 Phase II 1
Universitaetsklinikum Schleswig-Holstein AöR Academic 1 Phase II 1
New trials by year
2022
2
2023
3
2024
4
2025
4
← All indication landscapes